Vaccination of Elk (Cervus canadensis) with Brucella abortus Strain RB51 Overexpressing Superoxide Dismutase and Glycosyltransferase Genes Does Not Induce Adequate Protection against Experimental Brucella abortus Challenge by Pauline Nol et al.
ORIGINAL RESEARCH
published: 10 February 2016
doi: 10.3389/fcimb.2016.00010
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 1 February 2016 | Volume 6 | Article 10
Edited by:
Adel M. Talaat,
University of Wisconsin–Madison,
USA
Reviewed by:
Michael F. Minnick,
The University of Montana, USA
Qing-Ming Qin,
Jilin University, China
*Correspondence:
Pauline Nol
pauline.nol@aphis.usda.gov
†
Present Address:
Alana A. Pavuk,
Antech Diagnostics, Chapel Hill,
NC, USA
Received: 15 October 2015
Accepted: 18 January 2016
Published: 10 February 2016
Citation:
Nol P, Olsen SC, Rhyan JC,
Sriranganathan N, McCollum MP,
Hennager SG, Pavuk AA, Sprino PJ,
Boyle SM, Berrier RJ and Salman MD
(2016) Vaccination of Elk (Cervus
canadensis) with Brucella abortus
Strain RB51 Overexpressing
Superoxide Dismutase and
Glycosyltransferase Genes Does Not
Induce Adequate Protection against
Experimental Brucella abortus
Challenge.
Front. Cell. Infect. Microbiol. 6:10.
doi: 10.3389/fcimb.2016.00010
Vaccination of Elk (Cervus
canadensis) with Brucella abortus
Strain RB51 Overexpressing
Superoxide Dismutase and
Glycosyltransferase Genes Does Not
Induce Adequate Protection against
Experimental Brucella abortus
Challenge
Pauline Nol 1*, Steven C. Olsen 2, Jack C. Rhyan 1, Nammalwar Sriranganathan 3,
Matthew P. McCollum 1, Steven G. Hennager 4, Alana A. Pavuk 5 †, Phillip J. Sprino 6,
Stephen M. Boyle 3, Randall J. Berrier 6 and Mo D. Salman 7
1Wildlife Livestock Disease Investigations Team, Veterinary Services, Animal and Plant Health Inspection Services, United
States Department of Agriculture, Fort Collins, CO, USA, 2 Agricultural Research Services, United States Department of
Agriculture, National Animal Disease Center, Ames, IA, USA, 3Center for Molecular Medicine and Infectious Diseases, Virginia
Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA, 4National
Veterinary Services Laboratories, Veterinary Services, Animal and Plant Health Inspection Services, United States Department
of Agriculture, Ames, IA, USA, 5Department of Pathobiology and Microbiology, College of Veterinary Medicine and Biological
Sciences, Colorado State University, Fort Collins, CO, USA, 6Colorado Serum Company, Denver, CO, USA, 7Department of
Clinical Sciences, College of Veterinary Medicine and Biological Sciences, Colorado State University, Fort Collins, CO, USA
In recent years, elk (Cervus canadensis) have been implicated as the source of Brucella
abortus infection for numerous cattle herds in the Greater Yellowstone Area. In the face
of environmental and ecological changes on the landscape, the range of infected elk is
expanding. Consequently, the development of effective disease management strategies
for wild elk herds is of utmost importance, not only for the prevention of reintroduction
of brucellosis to cattle, but also for the overall health of the Greater Yellowstone Area
elk populations. In two studies, we evaluated the efficacy of B. abortus strain RB51
over-expressing superoxide dismutase and glycosyltransferase for protecting elk from
infection and disease caused by B. abortus after experimental infection with a virulent
B. abortus strain. Our data indicate that the recombinant vaccine does not protect elk
against brucellosis. Further, work is needed for development of an effective brucellosis
vaccine for use in elk.
Keywords: Brucella abortus, RB51, elk, wildlife vaccination, superoxide dismutase, O-side chain,
glycosyltransferase
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INTRODUCTION
The persistence of brucellosis in wild elk (Cervus canadensis)
remains a serious concern in the Greater Yellowstone Area
(GYA). In recent years, elk have been implicated as the
source of infection for numerous cattle herds in Wyoming,
Idaho, and Montana, USA (Hillman, 2002; Olsen et al.,
2006; Rhyan et al., 2013). Consequently, the development
of effective disease management strategies for wild elk herds
is of utmost importance, not only for the prevention of
reintroduction of brucellosis to cattle, but also for the overall
health of the GYA elk populations. A valuable component of
brucellosis management in wildlife would be utilization of an
effective vaccine that could be delivered mucosally. Currently
available commercial vaccines for use in cattle (B. abortus
strains 19 [s19] and RB51 [sRB51]) have offered little to no
protection in elk against Brucella-induced abortion and infection
(Cook et al., 2002; Kreeger et al., 2002; Olsen et al., 2002).
Vemulapalli et al. (2000a,b, 2002) have shown that recombinant
B. abortus sRB51 over-expressing antigenic factors in the form
of either homologous Cu/Zn superoxide dismutase (SODc)
or glycosyltransferase (encoded by wboA; McQuiston et al.,
1999) intra-cytoplasmically (sRB51+SODc, WboA), induces an
enhanced immune response and thus greater protection against
B. abortus challenge in mice as compared to vaccination with
sRB51 alone.
Strain RB51, a rough mutant of B. abortus, does not express
O-side chain, a component of the bacterium’s lipopolysaccharide
(LPS), which is essential for the structure and function of the
outer membrane of Gram-negative bacteria (Cardoso et al.,
2006). Glycosyltransferase is vital for O-side chain biosynthesis
of the LPS in Brucella spp. Additionally, it is the host antibody
response against the O-side chain that is detected by standard
Brucella serologic tests. Brucella LPS has been shown to
impair antimicrobial host responses (reviewed by Seleem et al.,
2008). Although, the LPS of Brucella species are less toxic
than LPSs of most other species of Gram-negative bacteria
(Forestier et al., 1999, 2000; Lapaque et al., 2005), studies
have demonstrated that Brucella LPS inhibits complement,
antibacterial-peptide activity, and host cell apoptosis, and
prevents production of immune mediators (Forestier et al.,
1999, 2000; Lapaque et al., 2005). These aspects allow Brucella
species to evade destruction and persist within phagocytic cells.
Also within the context of avoiding destruction, superoxide
dismutases have been demonstrated to influence the oxidative
environment of the host tissue and also play a role in
intracellular survival of Brucella (Break et al., 2012; Wareth
et al., 2015). Superoxide dismutases catalyze the dismutation of
oxygen radicals, thus preventing the effects of reactive oxygen
toxicity.
Our objectives were to investigate the efficacy of
sRB51+SODc, WboA in protecting elk against experimental
challenge with virulent B. abortus strain 2308 (s2308).
This investigation involved two separate controlled animal
trials. Our results indicated that sRB51+SODc, WboA
would not be effective in protecting elk from Brucella
abortus infection. Further, work is essential to develop
a protective vaccine to manage brucellosis in wild elk in
the GYA.
MATERIALS AND METHODS
Animals
Experiment 1
Twenty-one captive-raised adult female elk were obtained in
July, 2005 and housed at the United States Department of
Agriculture (USDA)/Colorado State University (CSU)-Animal
Population Health Institute outdoor wildlife research facility
(WRF) in Fort Collins, Colorado, USA. Elk were purchased
from a commercial herd in Minnesota, USA. This herd was
certified free of brucellosis, bovine tuberculosis, and chronic
wasting disease. The animals were acclimated for 6 wk at
the WRF prior to vaccination. Fifteen elk were vaccinated
intramuscularly (prime) with sRB51+SODc, WboA as described
below in September 2005; and a subset of eight animals was
orally boostered 6 wk after prime vaccination. Six animals
served as non-vaccinated controls. These animals were exposed
to bulls during the fall 2005 breeding season. In January
2006, elk were physically examined by rectal palpation for
pregnancy. Six pregnant animals of each vaccine group were
randomly selected for transportation in January, 2006 to a
large animal Biosafety Level-3 (ABSL-3) facility for B. abortus
s2308 challenge at the USDA, Agricultural Research Service,
National Animal Disease Center (NADC), Ames, Iowa, USA.
Only three elk in the control group were pregnant and were
sent to the ABSL-3 facility. Three additional pregnant elk were
obtained from the same commercial breeder and transported
directly to the ABSL-3 facility. Animals were maintained under
ABSL-3 conditions until the conclusion of the study in June,
2006.
Experiment 2
Twenty-nine adult female elk were obtained in January, 2008
from the wild in northeastern Oregon, USA, an area free of
chronic wasting disease, and brought to the WRF. Animals
were acclimated at the WRF for 2 mo before prime vaccination
in March of 2008. Fourteen animals were orally vaccinated
with sRB51+SODc, WboA. Fifteen animals served as controls.
Three animals in the control group died or were euthanized
within the first 5 months of the study as a result of injuries
or dystocia. Animals in the vaccinated group received booster
vaccinations in December 2008. Elk were exposed to bulls during
the 2009 fall breeding season. In December 2009, elk were
examined for pregnancy status using ultrasound (Ibex, E. I.
Medical Imaging, Loveland, Colorado, USA). Seven control cows
and 13 vaccinates were diagnosed as pregnant. Due to space
limitations, 11 randomly selected pregnant vaccinates and all
seven control elk were transported to the ABSL-3 facility in
February 2010 for experimental challenge. One vaccinate was
ultimately determined not to be pregnant at necropsy.
All animals in both experiments were housed, handled, and
cared for under protocols approved by the Institutional Animal
Care and Use Committees of CSU and NADC.
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Vaccine Preparation and Vaccination
Experiment 1
Brucella abortus sRB51+SODc, WboA was prepared for prime
vaccination at Virginia Polytechnic Institute and State University
(VaTech), Blacksburg, VA, USA, by growth on trypticase soy agar
plates for 48 hr at 37◦C and 5% CO2. The cells were harvested
in phosphate buffered saline (PBS; pH 7.4), concentrated by
centrifugation, washed twice in PBS and re-suspended in PBS.
Vaccine concentration was determined by standard plate counts.
The vaccine was then shipped overnight on ice to CSU, Fort
Collins, CO where it was stored at 4◦C for 24 hr before use.
For booster vaccination, sRB51 +SODc, WboA was
commercially prepared in lyophilized form (Colorado Serum
Company (CSC), Denver, Colorado, USA) and reconstituted and
used in accordance with manufacturer’s recommendations.
Twenty-one elk were randomly divided into three groups. The
first group (single dose; n = 7) received one intramuscular (IM)
injection in the left hip with 1ml of approximately 2×1010 colony
forming units (cfu) of sRB51+SODc, WboA (VaTech). The
second group (oral boost; n = 8): received one IM injection in
the left hip with 1ml of approximately 2×1010 cfu sRB51+SODc,
WboA (VaTech) and was orally boosted 6 wk later with 1.2ml
of approximately 1× 1011 cfu sRB51+SODc,WboA (CSC). Oral
inoculations were administered using an 8 French 16 inch urinary
catheter inserted to the back of the pharynx via a cylindrical
oral speculum. The third group (Control; n = 6) received 1ml
PBS IM in the left hip and served as controls. Controls were
housed separately from vaccinated animals to prevent exposure
to vaccine. Elk were transported to the ABSL-3 facility five mo
post-prime vaccination and allowed to acclimate for 4 wk prior
to B. abortus challenge.
Experiment 2
Twenty-nine captured elk were randomly divided up into two
groups. In March 2008 one group (n = 14) was orally inoculated
with a 5ml volume of approximately 1× 1011 cfu sRB51+SODc,
WboA prepared and provided by CSC, and orally boosted in a
similar manner in December 2008. The second group was orally
administered 5ml diluent (CSC) (Control; n = 15). Controls
were housed in a separate pen from vaccinated animals to prevent
exposure to vaccine. Elk were transported to the ABSL-3 facility
22 mo post-prime vaccination and allowed to acclimate for 2 wk
prior to B. abortus challenge.
Brucella abortus Preparation and
Challenge
For Brucella challenge in both experiments, smooth B. abortus
s2308 was grown on tryptose agar containing 5% bovine serum
for 48 hr at 37◦C and 5% CO2. Bacteria were harvested by
aspiration using saline. Suspensions of s2308 were adjusted to
approximately 1 × 107 cfu/ml by use of a spectrophotometer
(wavelength-600 nm) and concentrations of viable bacteria were
determined by standard plate counts.
At approximately mid-gestation in both experiments, animals
were anesthetized with xylazine (0.6–0.8mg/kg) and ketamine
hydrochloride (2.5–3.0mg/kg) IM and conjunctivally challenged
with 1× 107 cfu s2308 (50µl/eye).
Sample Collection and Processing
Blood Collection
Blood was collected via jugular venipuncture for serology prior to
vaccination in both experiments; at 1, 2, 4, 6 (boost), 8, 12, 17, 22,
and 30 wk after initial vaccination in Experiment 1; and at 2, 4,
8, 12, 14, 17, 21, 27 wk after initial vaccination in Experiment 2.
In Experiment 1, at 6 and 10 wk post-prime vaccination, blood
samples were collected for lymphocyte blastogenesis and flow
cytometry. At 6 and 14 wk after experimental challenge, blood
was collected for serology, lymphocyte blastogenesis, and flow
cytometry as described earlier. In Experiment 2, post-challenge
blood was obtained at 4, 8, and 12 wk for serology.
For both experiments, blood for serology was allowed to
clot for 2–4 hr at 4◦C, centrifuged, divided into 1-ml aliquots,
and frozen at −70◦C. Whole blood samples for lymphocyte
blastogenesis and flow cytometry were processed as described
below.
Serology
For both experiments, pre- and post-vaccination serum samples
were sent to the National Veterinary Services Laboratory for
brucellosis testing by standard card (CARD), standard plate
(PLATE), rivanol (RIV), buffered acidified plate antigen (BAPA),
complement fixation (CF), and fluorescence polarization assay
(FPA) (Alton et al., 1988; Nielsen et al., 2000; Rhyan et al.,
2009; Schumaker et al., 2010). In both experiments pre- and
post-vaccination, antibody titers at various time points against
sRB51 were determined by a previously described ELISA
procedure using gamma-irradiated sRB51 (Olsen et al., 1997,
2006) and a peroxidase-conjugated, mouse anti-goat IgG (heavy
and light chain-specific) used at a 1:3000 dilution (Jackson
Immunoresearch, West Grove, PA).
In both experiments, serum collected just prior to and after
experimental challenge with s2308 was evaluated using the
standard tube agglutination test (STAT) (Alton et al., 1988).
Lymphocyte Blastogenesis
At 6 and 10 wk post-vaccination (Experiment 1 only), and 6
and 14 wk post-challenge, whole blood was collected in an
acid-citrate dextrose solution and peripheral blood mononuclear
cells (PBMC) were prepared for lymphocyte blastogenesis and
cell proliferation assays, as described by Olsen et al. (2009).
Fifty microliter of PBS containing 5 × 105 cells, were added
to flat-bottom wells of 96-well microtiter plates that contained
gamma-irradiated s19 or sRB51 (109–105 bacteria/well). Wells
containing no antigen served as negative controls and wells
containing 1µg/ml pokeweed mitogen (Sigma Chemical Corp,
St. Louis, Missouri, USA) were used as positive controls for
proliferative responses. Cell proliferation results were converted
to stimulation indices (counts per minute [cpm] of wells
containing antigen/cpm in the absence of antigen) for statistical
comparisons.
Flow Cytometry
In Experiment 1 only, at 6 and 14 wk post-challenge,
aliquots of PBMC containing 2 × 107 cells were prepared
for and analyzed through flow cytometry as previously
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described (Olsen et al., 2009). Primary antibodies (VMRD,
Pullman, WA) included anti-CD4 (17D1-immunoglobulin
G [IgG]), anti-CD8 (ST8-IgM), anti-B cell (PIG45AIgG2b),
anti-γδTCR (GB21A-IgG2b), and anti-WC1 (BAQ4A-
IgG1). Secondary antibodies included peridinin chlorophyll
protein (1µg/ml)-conjugated rat anti-mouse IgG1 (Becton
Dickinson, Franklin Lakes, NJ, USA) and phycoerythrin
(1µg/well)-conjugated goat anti-mouse IgM or IgG2b (Southern
Biotechnology Associates, Birmingham, AL). Data were analyzed
using commercially available software: (CellQuest; Becton
Dickinson and Modfit;Verity Software House, Inc., Topsham,
ME, USA).
Necropsy and Tissue Collection
Twenty-four hr after parturition, cows were anesthetized and cow
and calf euthanized by intravenous administration of sodium
pentobarbital (88mg/kg; Fort Dodge Laboratories, Ft. Dodge,
Iowa, USA). Calves were considered viable if it was observed to
stand and showed evidence of having nursed (observed/milk in
stomach). Maternal samples obtained at necropsy included: lung,
liver, spleen, placentome/caruncle, mammary gland tissue, and
milk from all four quarters, lymphatic tissue (bronchial, hepatic,
internal iliac, mandibular, mesenteric, parotid, retropharyngeal,
prescapular, and supramammary), blood, vaginal swab, and
conjunctival swab. Fetal samples obtained included: lung, liver,
spleen, bronchial lymph node, gastric contents, rectal swab, and
blood.
Brucella Culture and Histopathologic Preparation
For Brucella culture, blood, other fluids, and swab samples
were inoculated directly on tryptose agar plates containing
5% bovine serum. Tissue samples were triturated in 0.85%
NaCl using a tissue grinder, and placed on tryptose agar
plates containing 5% bovine serum. After incubation at 37◦C
and 5% CO2 for 7 days, B. abortus was identified by colony
morphology and growth characteristics and confirmed by a
Brucella-specific polymerase chain reaction assay (Alton et al.,
1988; Lee et al., 2001). For histopathology, tissues were placed in
neutral buffered 10% formalin, embedded in paraffin, sectioned
at a thickness of 5µm, and stained with hematoxylin and
eosin.
Data Analysis
Serologic data obtained from ELISA, STAT, and data obtained
from proliferation assays were analyzed as the logarithm of the
value. STAT data that were negative at a 1:25 dilution were
converted to 1 prior to conversion to a log value. Data from
ELISA and STAT assays were compared over all time points
using a Two-way analysis of variance model (ANOVA), whereas
differences between groups in flow cytometry and [3H]thymidine
incorporation (lymphocyte blastogenesis) at each time-point
were compared by a general linear model procedure (SAS
Institute, Inc., Cary, NC). Means for individual treatments were
separated by use of a least-significant-difference procedure (P <
0.05). Numbers of culture positive tissues were compared among
groups using Fisher’s Exact Test (SAS Institute Inc.; P < 0.05).
RESULTS
Serology
Serologic data were obtained from the elk in order to
evaluate reaction to standard tests and sRB51 antigen after
vaccination with sRB51+SODc, WboA, as well as extent of
antibody responses to s2308 antigen in the face of B. abortus
challenge.
Experiment 1
All elk were negative on CARD, CF, and FPA tests prior to
vaccination. Transient positive responses on these serologic tests
occurred in both vaccine groups after vaccination. Animals
in both vaccination groups developed humoral responses that
caused positive responses on the CARD, CF, and FPA tests
at or after 2 wk post-prime vaccination, indicating response
to the overexpressed antigens in the vaccine. For the CF,
positive responses declined after 8 wk post-prime in both
vaccine groups, with a greater rate of decline in the single
dose treatment as compared to the oral boost treatment. For
the FPA, positive responses decreased after 4 wk post-prime
vaccination in the single dose group and in the oral boost
group after 6 wk post-prime vaccination. Positive responses on
the CARD test declined after 4 wk post-initial vaccination in
both groups. Data are represented in Figure 1. Most animals
in all three treatment groups were positive on PLATE, RIV,
and BAPA prior to initial vaccination (data not shown). These
data indicate that parenteral vaccination with sRB51+SODc,
WboA induces antibody production detectable on standard
Brucella tests for up to 8 wk, and that antibody levels in
the oral boost group lasted somewhat longer. The reason
for the pre-vaccination positive tests outcomes (PLATE, RIV,
and BAPA) is unknown and is addressed further in the
discussion.
Mean ELISA responses to sRB51 were greater (P < 0.05) in
the single dose group and the oral boost group at 4 and 6 wk
after initial vaccination as compared to serologic responses of the
control group indicating antibody production against sRB51 after
vaccination (Figure 2A).
Prior to experimental challenge with s2308, mean titers on the
STAT did not differ (P > 0.05) between groups. Both control
and single dose groups demonstrated seroconversion, indicating
significant antibody production in the face of B. abortus infection,
in that mean titers at 6 wk after challenge were greater (P < 0.05)
when compared to serologic data obtained prior to challenge.
Mean STAT titer of oral boost vaccinates after experimental
challenge did not differ (P > 0.05) from the mean titer prior
to challenge. Control animals had greater (P < 0.05) mean
STAT titers at 6 and 14 wk post-challenge, and at necropsy,
when compared to response of animals in oral boost group
and at 14 wk and necropsy when compared to the single dose
group.
Mean titers of oral boost and single dose groups were
significantly different from each other at 6 wk post-challenge
(Two-way ANOVA; p < 0.05) but did not differ (P > 0.05)
at any other sampling time. Increased antibody responses after
B. abortus challenge are indicative of response to infection.
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FIGURE 1 | Experiment 1: Percent positive elk in each vaccine group as
measured on three standard brucellosis tests at multiple time points:
Complement Fixation Assay (CF), Fluorescence Polarization Assay
(FPA), and Standard Card Test (CARD). Animals in both vaccination groups
developed antibodies that caused positive responses at or after 2 wk
post-prime vaccination on all three tests. Positive responses on CF declined
after 8 wk post-prime in both vaccine groups. Positive responses to FPA
decreased after 4 wk post-prime vaccination in the single dose group and
after 6 wk post-prime vaccination in the oral boost group. Positive responses
on the CARD test declined after 4 wk post-prime vaccination in both groups.
Elk in the single dose and oral boost groups were vaccinated with 2× 1010
colony forming units sRB51+SODc, WboA intramuscularly (0 wk) and elk in
the oral boost group were orally vaccinated with 1× 1011 colony forming units
sRB51+SODc, WboA at wk 6. The control group received phosphate buffered
saline intramuscularly.
Although, it is not clear what the differences in responses among
the vaccine groups and controls indicate, it may be that the oral
boost group had reduced antibody responses to infection via
the mucosa route in the face of mucosal delivery of the booster
vaccine (see Table 1).
FIGURE 2 | (A,B) Differences in antibody responses (ELISA; mean optical
density ± SEM) to sRB51 between vaccination groups at multiple time points
in Experiment 1 (A) and Experiment 2 (B). (A) In Experiment 1, mean
responses to sRB51 were greater (P < 0.05) in the single dose group and the
oral boost group at 4 and 6 wk after initial vaccination as compared to
serologic responses of the control group. Elk in the single dose and oral boost
groups were vaccinated with 2× 1010 colony forming units sRB51+SODc,
WboA intramuscularly (0 wk) and elk in the oral boost group were orally
vaccinated with 1× 1011 colony forming units sRB51+SODc, WboA at wk 6.
The control group received phosphate buffered saline intramuscularly. (B) In
Experiment 2, mean responses to the sRB51 were greater (P < 0.05) in the
vaccinated group at 4, 8, 12, 14, 17, 21, and 27 wk after initial vaccination as
compared to controls. Elk in the vaccinate group were orally vaccinated with
1× 1011 colony forming units sRB51+SODc, WboA at wk 0. Elk were
boosted with the same preparation at wk 40 although this figure does not
reflect antibody responses post-booster. The control group received diluent
orally. In both figures, bars with differing letters differ significantly from each
other (p < 0.05).
Experiment 2
With the exception of one vaccinated elk that was positive on
the PLATE and one control that was positive on the CARD,
the remaining elk were negative on all serologic tests prior
to initial vaccination. Pre-vaccine serology was not performed
on five elk in the vaccination treatment due to accidental loss
of samples. At 3 wk post-vaccination, seven of 13 vaccinates
tested were positive on PLATE and one animal was positive
on BAPA, FPA, and CARD as well. Three of 15 control
animals tested at this time point were also positive on PLATE.
Animals were sporadically positive on BAPA, PLATE, and
FPA after booster vaccination; however these results were
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TABLE 1 | Elk Serum Tube Agglutination Test titers (± SEM) at various time points after challenge with 107 cfu Brucella abortus s2308 and at necropsy.
Day 0 4 wk PC 6 wk PC 8 wk PC 12 wk PC 14 wk PC Necropsy Calf
EXPERIMENT 1
Single Dose 4 ± 4a ND 29 ± 15b ND ND 8 ± 5ac 4 ± 4a 4 ± 4a
Oral boost 0 ± 0a ND 12 ± 8ac ND ND 8 ± 8a 0 ± 0a 0 ± 0a
Control 0 ± 0a ND 133 ± 54b ND ND 58 ± 14b 21 ± 8c 6 ± 6ac
EXPERIMENT 2
Oral 0 ± 0a 35 ± 12c ND 20 ± 7c 5 ± 3a ND 5 ± 3a 0 ± 0a
Control 0 ± 0a 146 ± 46b ND 76 ± 21b 25 ± 8c ND 4 ± 4a 4 ± 4a
Values superscripted with different letters within experiments are significantly different from each other. wk, weeks.
ND, not done; PC, post-challenge.
isolated and no positive responses were detected over two or
more consecutive time points (data not shown). These results
indicate that oral sRB51+SODc, WboA vaccination induces
transient antibody production detectable on standard Brucella
tests.
Mean ELISA responses to the sRB51 were greater (Two-way
ANOVA; P < 0.05) in the vaccinated group at 4, 8, 12, 14, 17,
21, and 27 wk after initial vaccination as compared to controls
(Figure 2B).
Mean STAT titers did not differ (P > 0.05) between
control and oral vaccination groups prior to challenge. Similar
to the first experiment, both the vaccine and control groups
demonstrated greater (P < 0.05) mean STAT titers at 4 and 8
wk after challenge when compared to mean titer of sera obtained
prior to challenge. Also, similar to responses in Experiment 1
after challenge, mean titers of the control group were greater
than those of vaccinates (P < 0.05) at 4, 8, and 12 wk
after challenge, but responses did not differ significantly at
necropsy. Again, it unclear what these differences in antibody
responses indicate, but they may be associated with responses
to mucosal vaccination followed by mucosal B. abortus challenge
(see Table 1).
Lymphocyte Blastogenesis
Experiment 1
Lymphocyte proliferative responses of PBMC to irradiated sRB51
were greater (P < 0.05) in the oral boost group at 6 (4.4-
fold difference) and 10 wk (12.6-fold difference) after initial
vaccination when compared to mean responses of PBMC from
non-vaccinated elk. Mean responses of PBMC from the single
dose group did not differ (P > 0.05) at 6 and 10 wk from
responses of elk in the oral or control treatment groups. At 14
wk after challenge PBMC from the oral boost group had greater
mean proliferative response as compared to the control group
(28.3-fold difference; P < 0.05). Mean proliferative responses
of PBMC obtained from elk in the single dose group at 6
and 14 wk and from the oral group at 6 wk after challenge
differed, but not significantly (P > 0.05), to mean responses
in the control group (data not shown). These results indicate
evidence of increased cellular immune response to sRB51 antigen
in the face of vaccination in the oral boost group as well
as at 14 wk after challenge as compared to non-vaccinated
animals.
Flow Cytometry
Experiment 1
At 6 wk post-challenge, there were no significant differences
among the three groups regarding proliferative responses to
killed sRB51 by any of the cell types evaluated. At 14 wk post-
challenge PBMC obtained from the oral boost group produced
greater (P < 0.05) total cell proliferation than PBMC obtained
from the single dose or control groups (Table 2). This is
consistent with the increased cellular immune responses seen
in the lymphocyte blastogenesis data obtained from the oral
boost group post-challenge. Analysis did not identify any other
differences in flow cytometric data.
Parturition and Necropsy
Calves
Numbers of abortions were documented in both experiments
in order to evaluate the efficacy of sRB51+SODc, WboA in
preventing abortions after infection.
Experiment 1
All animals in the single dose group (n = 6) and all animals
in the oral boost group (n = 6) gave birth to live calves;
however one calf in the single dose group was not considered
viable based on clinical assessment and lack of milk in its
abomasum. In the control group, two of six cows gave birth
to dead calves and one calf was considered not viable. There
were no significant differences among the three groups regarding
numbers of abortions (Fisher’s Exact Test; p ≥ 0.05) or numbers
of abortions and non-viable calves combined (p > 0.05; see
Table 3).
Experiment 2
All of the animals except one non-pregnant vaccinate gave birth
to live calves. No abortions or non-viable calves were observed.
Culture
Culture data were obtained from various tissues in both
experiments in order to evaluate the efficacy of sRB51+SODc,
WboA in preventing or reducing colonization of these tissues in
the face of B. abortus infection.
Experiment 1
B. abortus was recovered at necropsy from at least one tissue
in five vaccinated elk, with two of six elk culture positive
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TABLE 2 | Experiment 1: Mean flow cytometric responses (± SEM) to sRB51 after challenge with 107 cfu B. abortus s2308.
Time after challenge Vaccine Groupb Cell type
Totala CD4+ CD8+ γδTCR+ IgM+
6 wk Single dose 55 ± 462 0 ± 0 778 ± 939 149 ± 227 388 ± 499
Oral boost 895 ± 1503 58 ± 297 404 ± 571 732 ± 762 388 ± 499
Control 0 ± 0 0 ± 0 61 ± 785 55 ± 48 109 ± 134
14 wk Single dose 191 ± 383 0 ± 0 0 ± 0 767 ± 556 332 ± 316
Oral boost 3002 ± 1344c 330 ± 681 1372 ± 904 1307 ± 680 117 ± 199
Control 111 ± 431 0 ± 0 250 ± 214 450 ± 214 62 ± 51
aMean proliferating cells per 10,000 PBMC ± standard deviation.
bn = 5/Vaccine Group.
cSignificantly different from other two groups.
TABLE 3 | Percentage and number of abortions or animals with specific tissue types positive for B. abortus s2308 in each group.
Vaccine Group Abortionsa Fetal tissuesa,b Repro/Mammary tissuesa,c Other tissuesa,d Any tissue
EXPERIMENT 1
Single dose 0 (0/6) 17 (1/6) 33 (2/6) 33 (2/6) 33 (2/6)
Oral boost 0 (0/6) 17 (1/6) 17 (1/6) 50 (3/6) 50 (3/6)
Control 33 (2/6) 17 (1/6) 67 (4/6) 83 (5/6) 83 (5/6)
EXPERIMENT 2
Oral vaccinate 0 (0/10)e 40 (4/10)e 10 (1/10)e 64 (7/11) 82 (9/11)
Control 0 (0/7) 57 (4/7) 29 (2/7) 57 (4/7) 100 (7/7)
a% (Number of aborted or infected/total).
bFetal Tissues included lung, liver, spleen, bronchial lymph node (ln), gastric contents, cerebral spinal fluid, rectal swab, blood.
cReproductive (Repro)/mammary tissues included milk, mammary gland, vaginal swab, supramammary ln, placentome.
dOther Tissues included lung, liver, spleen, lymphatic tissue (bronchial, hepatic, internal iliac, mandibular, mesenteric, parotid, retropharyngeal, and prescapular), blood, and conjunctival
swab.
eOne vaccinated elk not pregnant and therefore not included in this category.
in the single dose and three of six in the oral boost group.
Brucella abortus was recovered from tissue samples of five of
six controls. Two of six animals in the single dose group and
one of six in the oral boost group were culture positive in
reproductive/mammary tissues (supramammary lymph node,
milk, mammary gland, placentome/caruncle, and/or vaginal
swab). In comparison, four of the six controls were culture
positive for reproductive/mammary tissues. Groups did not differ
(P > 0.05) when number of animals culture positive for Brucella
were compared or when reproductive, fetal, or other maternal
tissue groups were compared (Fisher’s Exact Test; p ranging from
0.35 to 1.0). Two of 12 calves in vaccination groups (one each for
single dose and oral boost groups) were culture positive. Brucella
was recovered from one of six calves in the control group. This
culture-positive fetus was one of the two abortions that occurred.
The other aborted fetus was negative on culture. The two calves
considered non-viable were culture negative as well (see Table 3
and Table S1).
Experiment 2
Seven of 10 pregnant elk in the vaccination group were culture
positive for B. abortus at necropsy from at least one tissue type
with only one animal positive for recovery of Brucella from
mammary or uterine tissues. In comparison, six of the seven elk
in the control group were culture positive on at least one tissue
type with Brucella recovered from mammary or uterine tissues
of two of seven cows. Four of seven calves in the control group,
and four of 10 calves in the vaccination group were positive
for recovery of B. abortus. The vaccine group did not differ
(P > 0.05) from the control treatment in regards to incidence
of recovery of Brucella, either overall or in the fetal, reproductive,
or maternal tissues (Fisher’s Exact Test; p ranging from 0.4 to 1.0;
see Table 3 and Table S2).
Although it appeared that B. abortus was recovered in more
control animals after challenge than in vaccinates in the first
experiment, these differences were not significant. Therefore,
neither experiment indicated a reduction of tissue colonization
by B. abortus due to sRB51+SODc,WboA vaccination.
Histopathology
Experiment 1
Microscopic lesions were identified in the mammary glands,
uterus, liver, and placenta of the cow, and lung and liver of
the fetus. Mammary glands of two of six cows in the single
dose treatment, one of six in the oral boost treatment, and no
cows in the control treatment displayed mild to moderate, focal,
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lymphoplasmacytic, or suppurative interstitial mastitis. Uterine
lesions including mild to moderate endometritis with mixed
inflammatory cell infiltrates were detected in five of six elk in the
single dose treatment, four of six elk in the oral boost treatment,
and two of six controls. Maternal carunculitis was seen in four
of six elk in the single dose group, four of six in the oral
boost group, and in two of six controls. Severity of carunculitis
ranged frommild to marked with degenerate cells and neutrophil
infiltrates. In some elk, focal hypercellularity in the interstitium
of the caruncles was observed, composed of large mononuclear
cells and focal accumulations of lymphocytes, plasma cells,
and scattered neutrophils. One of the six elk in the oral
boost group had multifocal, random, lymphoplasmacytic, and
suppurative hepatitis, with occasional hepatocellular necrosis.
Two calves from the single dose group had lymphoplasmacytic
and suppurative interstitial pneumonia. Moderate to marked,
multifocal, suppurative hepatitis with hepatocellular necrosis was
also observed in one of these calves. Only one of the elk (control
group) had histopathologic lesions that were associated with a
positive tissue culture (see Table S1).
Experiment 2
Mammary glands of all vaccinated and six of seven control
elk displayed marked glandular atrophy and degeneration, with
dilation and inspissation of secretory material, surrounded by
mixed chronic interstitial inflammation. With the exception of
one cow, mild to marked, suppurative splenitis with lymphoid
hyperplasia were observed in all elk but severity did not appear
to differ between groups. Submandibular lymph nodes of all
controls and six of nine vaccinated elk displayed mild to
moderate suppurative lymphadenitis with lymphoid hyperplasia.
Mild to marked diffuse suppurative placentitis was observed in
six of seven controls and 10 of 10 vaccinates. Fetal lungs from
four of seven controls and seven of 10 vaccinates displayed
mild to moderate suppurative interstitial pneumonia. Mastitis,
lymphadenitis, and placentitis lesions were slightly more severe
in vaccinates as compared to controls. Recovery of Brucella did
not appear to be associated with presence or severity of lesions
(see Table S2).
DISCUSSION
Data from our two controlled efficacy studies suggest that
parenterally and/or orally administered sRB51 + SODc, wboA
did not induce significant levels of protection in elk against
experimental B. abortus challenge. Based on encouraging
data observed in mice (Vemulapalli et al., 2000a,b, 2002),
we anticipated that mucosal vaccination with an RB51
strain that overexpresses both superoxide dismutase and
glycosyltransferase, antigens that are immunogenic and
associated with virulence, would elicit a protective response in
elk. Elzer and Davis (1997) reported observing partial protection
against abortion in elk orally vaccinated with 1010 cfu sRB51 and
challenged 2 mo after inoculation. However, their results were in
contrast to subsequent studies in elk performed by Cook et al.
(2002) and Kreeger et al. (2002) where abortions and infection
were not prevented by vaccination with parenteral sRB51 (hand
injection and biobullet) when compared to non-vaccinated
controls. In addition, in a controlled study in bison, parenteral
sRB51 + SODc, wboA offered even less protection than the
parenteral sRB51 strain, which was effective in preventing
abortion and reducing infection in bison (Olsen et al., 2009,
2015).
Our conclusion regarding the lack of efficacy of sRB51 +
SODc, wboA in elk was based on tissue culture alone, as we did
not induce significant numbers of abortions in non-vaccinates
after experimental challenge. A lack of efficacy of the vaccine
strain is also supported by culture and histopathology data which
demonstrated infection and histologic lesions without significant
differences in these parameters between vaccinates and controls.
We were surprised that high numbers of abortions were not
observed since high numbers of elk in both groups were culture
positive for the challenge strain. It remains unclear as to why
experimental challenge using the standard ruminant challenge
model (1 × 107 cfu s2308 conjunctivally in mid-gestation) did
not induce high numbers of abortions, particularly in control
elk. Cook et al. (2002) and Kreeger et al. (2002) successfully
induced abortions in the majority of their elk using a similar
dose of s2308, and the same inoculum as was used in this study
effectively caused abortions in a parallel experiment in bison
(Olsen et al., 2015). Similarly prepared challenge inocula induced
significant numbers of abortion in non-vaccinated cattle (Olsen
and Johnson, 2011). Data have demonstrated immunologic
differences between elk and cattle in responses to tuberculosis
and brucellosis vaccines (Waters et al., 2003; Olsen et al.,
2006), which may alter the pathologic mechanisms associated
with induction of abortion. One example might include the
observation that serum tube agglutination antibody titers were
generally lower than those observed in bison and cattle after
experimental challenge (Olsen and Johnson, 2011). Our data
suggest a need for further studies to establish a more consistent
and reliable model for evaluation of vaccine efficacy against
brucellosis in elk that mimics pathologic effects under field
conditions.
It is interesting that lesions of placentitis and fetal interstitial
pneumonia commonly associated with B. abortus infection
were found in the challenged elk and their calves from
which the challenge strain was not recovered. It cannot be
eliminated that these lesions may reflect Brucella infection
despite the failure to recover the challenge strain from the tissue
samples. Alternatively, these lesions may have represented other
pathologic conditions that we cannot diagnose at this time.
Although a majority of vaccinated elk in the first experiment
were serologically positive prior to vaccination, these seropositive
responses were in three Brucella tests used for screening.
Screening tests are known for having high sensitivity but
relatively lower specificity. As these animals originated from
a brucellosis-free captive herd in a brucellosis-free state
(Minnesota, USA), we believe it is highly unlikely they had been
exposed to brucellosis. It is far more likely that the animals
developed antibodies after infection with one of the various
organisms that are known to cause cross-reactions on brucellosis
serologic tests. Yersinia enterocolitica O:9 is one example as it
possesses an identical lipopolysacharide to B. abortus and has
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been reported in numerous studies as a cause of false positive
serologic responses on brucellosis tests (Weynants et al., 1996;
Garin-Bastuji et al., 1999). However, as other bacteria have also
been identified as being capable of causing cross-reactors in
brucellosis serologic tests, it cannot be excluded that they may
have been responsible for the false-positive responses in the
current study (Nielsen et al., 2004).
Current regulations require that Brucella-infected animals
be held under ABSL-3 conditions which is expensive and to
some extent limits experimental units in a study. We cannot
exclude the possibility that statistical differences in infection or
abortions between experimental groups may have been detected
if greater sample sizes were evaluated. However, numbers of the
animals in the current experiment should have been sufficient
to identify a protective vaccine that would be suitable for use
under field conditions. As delivery of vaccine to a free-ranging
population will most likely be expensive and complicated, only
those vaccines that demonstrate high levels of protection under
controlled experiments are likely candidates for consideration
of further evaluation under field conditions. Although sRB51 +
SODc, wboA did appear to slightly reduce infection in the two
studies, as compared to controls, this effect was marginal in
preventing fetal, mammary, or uterine infection. Therefore, the
data suggest its effect on disease prevalence under field conditions
would be limited, and therefore further evaluation of this vaccine
in elk is not warranted.
Development of a highly efficacious vaccine that protects elk
against B. abortus infection has yet to be achieved. Continuation
of efforts to develop a brucellosis vaccine in elk is important, as
elk have been implicated as the source of Brucella infection in a
number of cattle herds in the GYA and vaccination could serve as
a vital component for reducing disease prevalence in elk. Future
studies not only need to contribute to development of a more
protective brucellosis vaccine for elk, but should also improve
the Brucella challenge model for elk such that it mimics clinical
characteristics of the disease under field conditions. Development
of a protective vaccine that can be effectively delivered to free-
ranging elk populations would be a valuable resource for agencies
with responsibilities related to brucellosis control ormanagement
of elk in the GYA.
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